共 94 条
[1]
Mandell BF(2008)Clinical manifestations of hyperuricemia and gout Cleve Clin J Med 75 S5-S8
[2]
Garay RP(2012)Antibodies against polyethylene glycol in healthy subjects and in patients treated with PEG-conjugated agents Expert Opin Drug Deliv 9 1319-1323
[3]
El-Gewely R(1956)Purification and properties of solubilized uricase Biochim Biophys Acta 21 290-298
[4]
Armstrong JK(2008)PEG-uricase in the management of treatment-resistant gout and hyperuricemia Adv Drug Deliv Rev 60 59-68
[5]
Garratty G(2008)The impact of PEGylation on biological therapies BioDrugs 22 315-329
[6]
Richette P(2011)Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials JAMA 306 711-720
[7]
Hudson PB(2012)Pegloticase: a new biologic for treating advanced gout Int J Clin Rheumatol 7 143-154
[8]
London M(2007)Rasburicase represents a new tool for hyperuricemia in tumor lysis syndrome and in gout Int J Med Sci 4 83-93
[9]
Sherman MR(2007)Antibody against poly(ethylene glycol) adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients Cancer 110 103-111
[10]
Saifer MG(2007)Pharmacokinetics and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in patients with refractory gout Arthritis Rheum 56 1021-1028